Bio Essence Corp (BIOE): Revenue
$1.90M
Year ended 2025-12-31
$2.91M
Trailing 12 months to 2026-06-30
+45.1%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.90M | +485.8% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $323.9K | -41.3% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $551.5K | -11.3% | 2024-04-15, From 2023-01-01 |
| 2022-12-31 | $621.6K | n/c | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | $888.0K | -7.4% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $958.7K | n/a | 2022-03-31, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Bio Essence Corp (BIOE) | 2025-12-31 | $1.90M | +485.8% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $1.98M | -82.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $2.04M | -67.3% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $2.07M | +3.7% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $1.63M | +58.9% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.49M | -37.1% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $1.45M | n/a |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.40M | n/a |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $1.38M | -0.3% |
Compare BIOE, LPCN, DNTH, KRSA side by side · Screen every company in Pharmaceutical Preparations ↗